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This research examines the importance of proximity and the role of distance 
within the life science sector of the economy for the interacting metropolitan regions of 
Denver and Boulder, Colorado and Triad and Triangle, North Carolina.  This sector is 
characterized by high technology employment, research and development, and 
knowledge spillovers.  The thesis of this research is that synergies among sectors within 
the life science industry exist between proximate places to build a regional economic 
growth engine.  Denver/Boulder, CO and Triad/Triangle, NC are complementary regions 
which share benefits of interactions within the growing life science sector of the economy 
because of proximity, strong commuting ties, a solid university system, and adequate 
research funding.  Statistics and data regarding labor sources and employment, 
commuting patterns, and funding come from the Bureau of Labor Statistics, 
ReferenceUSA Employment database, Census Transportation Planning Package, and the 
National Institute of Health.  Employment figures are classified by selected life science 
sectors within the North American Industry Classification System (NAICS).  Analysis of 
these statistics will demonstrate the clustering of life science employment, ease of 
mobility within the regions, and strength of research and development within the study 
areas. Conclusions demonstrate that proximate places in Colorado and North Carolina 
possess the attributes necessary to maintain a successful economic environment for the 
life science industry to develop.   
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CHAPTER I 
 
INTRODUCTION 
 
 
Metropolitan areas seek to attract clusters of firms related to the life science industry 
since this sector tends to be highly profitable.  A major question remains as to why some groups 
of cities are more successful at nurturing firms in certain components of this industry than are 
other urban areas.  A region can be measured at various scales but is defined here as a group of 
proximate Metropolitan Statistical Areas (MSAs) or Combined Statistical Areas (CSAs).  The 
MSAs chosen for analysis are grouped into CSAs, which are defined by the U.S. Census Bureau 
as an aggregate of adjacent MSAs that are linked by commuting ties (U.S. Census Bureau 2008).  
Some metropolitan locations attract successful, high-technology clusters while others are less able 
to do so.  The role of place is an important consideration in the location of life science activities.  
Why do companies choose one place over another?  
The thesis of this research is that synergies among sectors within the life science industry 
exist between proximate places that can build a regional economic growth engine.  It is 
hypothesized that each MSA in this group selected tends to develop its own specialization within 
the life science industry.  Even with specializations that are unique to each MSA, firms within life 
sciences tend to cluster in a proximate sense.  Life science industry clusters and specializations by 
MSA will be demonstrated through the use of Bureau of Labor Statistics (BLS) and 
ReferenceUSA company database information. Another part of the hypothesis of this research is 
that life science firms establish their locations in regional clusters and develop strategies for 
innovation and collaboration to benefit from synergies and regional growth.  This will be 
demonstrated through the use of company surveys.
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This research examines the importance of proximity and the role of distance within the 
life science sector of the economy using case studies of CSAs in Colorado and North Carolina.  In 
Colorado, the proximate MSAs of Boulder, Denver, and Greeley are studied.  In North Carolina, 
the proximate CSAs of Greensboro - Winston-Salem - High Point (known as the Triad) and 
Raleigh – Durham – Cary (known as the Triangle) are studied.  The Triad CSA contains three 
MSAs and the Triangle consists of two.  The MSA and CSA definitions for the year 2006 are 
used.  They change according to population patterns and decisions made by the U.S. Census 
Bureau and Office of Management and Budget.  Some of the data presented uses previous MSA 
definitions.  The Research Design section articulates the reason for choosing these MSAs as study 
regions and their rankings in terms of employment within selected life science sectors. 
It is asserted that the regions of Denver/Boulder, CO and Triad/Triangle, NC are each 
complementary regions which share the benefits of interactions within the growing life science 
sector of the economy because of the location of employment clusters, strong commuting ties 
between the proximate MSAs and CSAs, and highly ranked research institutions in terms of grant 
funding.  These regions benefit economically from the development of biopharmaceutical 
industry clusters.  They are highly connected with their local university systems, thus attracting 
high-technology firms and employment and providing a highly skilled and highly educated 
workforce.  There is a sense of communication relationships which result in knowledge flows and 
spillovers.  The industry is experiencing high rates of growth in these economically vibrant 
regions because corporations, businesses, and universities learn from each other.   
The life sciences industry is important to study since their R&D branches apply 
biological knowledge and techniques related to molecular, cellular, and genetic processes to 
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develop products and services, generating high revenues for their harboring locales.  
Biotechnology remains a fairly new industry with approximately 40% of existing firms less than 
15 years old (Hall and Bagchi-Sen 2007).  The industry consists of firms which establish 
themselves to develop this knowledge and involves the creation of new ideas through research 
and development of new products and processes (Cortwright and Mayer 2002).  This new and 
rapidly changing industry has a great impact on the health, quality of life, and life span of the 
human race.  One significant achievement is recombinant DNA technology which has resulted in 
proteins that are already used as therapeutics.  Antibodies for cancer, arthritis and tissue 
transplant, growth hormones, and clot-busting enzymes have been also been discovered by top 
scientists and researchers within the industry (DeVol et al. 1994).   
Funding and support are available in the form of National Institute of Health (NIH) grant 
funding, private sector investments, venture capitalists, and research and development (R&D) 
contracts.  NIH funding data will be used as a proxy to represent all of these sources of support.  
The literature review in the next section includes a discussion of collaboration, alliances, and 
innovation within the biopharmaceutical industry, strategies for cluster development, knowledge 
flows, funding sources, and research facilities.  The data presented in the Findings section will 
show that the important characteristics of life science clusters exist and aid in regional economic 
growth in key metropolitan clusters in both Colorado and North Carolina.   
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
2.1  Synergies Among Sectors Within the Same Industry 
 
High-technology related businesses generally locate in a place so they can benefit from 
the synergies created through human interaction and easy access to a university‟s researchers, 
students, facilities, programs, and equipment (Rosenblum 2004).  Core high technology areas are 
characterised by a synergistic combination of growth in employment, product and process 
innovation, and high rates of local business formation, all operating to obtain high levels of 
agglomerative advantage (Lyons 1995).  Firms containing higher levels of R&D are presented 
with more opportunities for collaboration (Hall and Bagchi-Sen 2007).  
Regional hot spots help to create new jobs and business ventures from technological 
discovery and inventions that are important for an innovation infrastructure.  One survey of 
biotech firms suggests that access to highly-skilled labor is a critical factor for activities that 
involve R&D (St. John and Pouder 2006).  Biopharmaceutical is a field where high-technology 
professional employment, ability to license technology, and access to venture capital are 
important.  Low R&D intensity firms place more importance on proximity to major customers 
because they may be actively involved or interested in new product development.  Innovation 
performance is most often a function of firm-level characteristics wherein technology is 
integrated throughout the innovation process (Hall and Bagchi-Sen 2007).  Firms need carefully 
planned and executed strategies for research, product development, manufacturing, marketing, 
and distribution in order to achieve competitive advantage
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A firm‟s commitment to R&D expenditure is critical to innovation performance.  The 
general definition of R&D intensity is the percentage of firm revenues spent on R&D.  This is 
considered an incurred expense so research could sometimes have a negative effect on innovation 
measurements.  R&D productivity is better measured by research-based rather than production-
based innovation.   Data suggest that high levels of R&D intensity are associated with high levels 
of domestic patent applications, international patent applications, domestic patent approvals, and 
international patent approvals (Hall and Bagchi-Sen 2007).  In the case of many firms, there 
could be a significant lag time between investment in research and eventual growth in business 
performance.  High R&D intensity firms place higher levels of importance on access to 
universities, other biopharmaceutical firms, and firms in related industries.   
2.1.1 Collaboration and Alliances 
  
Several important innovation strategies seek to ensure success in biopharmaceutical firms 
including university alliances, licensing agreements, export-import connections to alliances for 
R&D, product development, and marketing. The strength of an area‟s local science base is closely 
correlated with new firm formation, especially in the therapeutics and diagnostics sectors 
(Bagchi-Sen 2007).  One strategic consideration presented includes increasing the number of 
university and industry candidates in which firms can associate with investors and collaborators.  
Another strategy is to license-in technologies from other firms and use their expertise.  There are 
many good reasons for considering inter-firm strategic alliances: accessibility of funds, reduction 
of risk, quality control in R&D, product development and manufacturing for large scale trials, and 
getting attention of third party investors.  A mutual benefit is apparent, where large firms benefit 
from alliances with smaller firms and vice versa (Bagchi-Sen 2007).  Smaller firms often seek 
assistance from larger firms for clinical trials, manufacturing, sales, and marketing which help 
maintain a continuous revenue stream.  Over 50% of all respondents in a recent study of life 
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biopharmaceutical firms in the U.S. noted the critical importance of developing alliances with 
large non-biopharmaceutical companies.  Firms with high R&D intensity levels earn over 60% of 
their revenues from royalty and/or licensing agreements or contracts.  The primary focus is on 
production and commercialization if a firm earns a greater amount of revenue from product sales.  
Younger firms tend to concentrate resources on research, product development, licensing 
technology, and collaborating to innovate (Hall and Bagchi-Sen 2007).  The Data and 
Methodology section includes statistics from a survey conducted in North Carolina related to 
innovation strategies. 
2.1.2  Innovation Systems  
A regional innovation system (RIS) differs from a cluster in that it can span several 
different sectors and clusters rather than being composed of a concentration of organizations 
within the same or similar industrial sector.  A sectoral innovation system (SIS) focuses more on 
the impact of specific knowledge bases and innovation processes and is defined as a group of 
firms working to develop and make a sector‟s product and utilize its technologies.  They tend to 
be more concerned with the impact of different technological regimes on innovation processes 
than an RIS would be (Coenen, et al. 2006).  A regional perspective is important for analyzing 
innovation interaction and inter-organizational learning processes because it emphasizes the 
importance of personal relationships and networks for economic activities.  This research defines 
regions as proximate, inter-related combinations of cities which encompass urban areas.    
A decline in the R&D power of large corporations is occurring along with the increase of 
specialist research firms (Cooke 2004).  Many government agencies are interested in developing 
policies to network regional innovation systems.  The mode of knowledge production shifted 
because of the rise in research.  Many dedicated biotechnology firms (DBFs) are initiating 
leading-edge research in clusters where large pharmaceutical firms are linked to research 
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institutes and other DBFs.  Many DBFs are heavily involved in knowledge generation but still 
need large pharmaceutical firms to assist in funding.  Research DBFs are able to bring together 
skilled researchers and technologists to target specific areas (Cooke 2004).  Several large 
companies developed and released drugs due to research conducted by university and private 
research scientists (i.e. Novartis, and Glivec).  Knowledge production is strongly regionalized in 
many clusters because of the importance of university and research institute laboratories to 
clusters of DBFs and the support of venture capitalists and other business services. 
2.2 Proximate Places 
Several studies found that companies with similar interests and business like to cluster in 
close proximity.  Industry clusters are part of a popular development practice useful for policy-
makers, community leaders, and everyday citizens to better understand regional economies.  
Regional clusters may form because of trading relationships and/or to share markets and 
knowledge resources (Feser and Luger 2003).  Clusters can have a significant, positive impact on 
the regional economies in which they reside.  The Milken Institute defines an industry cluster as 
“a geographic concentration of sometimes competing, sometimes collaborating firms, and their 
related supplier network” (DeVol et al. 1994: 1).  Interrelated life science industries generate 
wealth within a regional economy.  Important factors in the development of life science clusters 
include proximity to research institutions, a supportive entrepreneurial culture, risk financing, and 
the availability of real estate (Walcott 2002).  Competitive advantage is maintained when 
companies cooperate in a shared place.  Government officials advertise a variety of regional 
features that may be appealing to high technology firms, including research universities, generous 
financial institutions, and political support.   
On the global scale, “places of high skill, high wage labor such as involved in research 
and development activities will attract businesses in the most developed countries, while lower 
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paying and less skill-demanding jobs will cluster in less developed countries” (Walcott 2001).  
This is known as the new international division of labor which plays a large role in the location of 
biotechnology activities.  Walcott (2001) used core (United States) and semi-periphery (China) 
areas to categorize R&D and manufacturing sites of high tech activities.  R&D occurs in core 
regions and while manufacturing and product packaging, processing, and handling occur in the 
semi-periphery.  Regional and urban land planners are increasingly looking toward the 
biotechnology industry for long term economic growth opportunities.  Knowledge flows through 
professional associations and informal relationships between individuals can result in knowledge 
spillovers being created within a cluster (Phene and Tallman 2002).  The Marshall-Arrow-Romer 
(MAR) externality predicts that industries cluster geographically to absorb knowledge that spills 
over from other firms.  Part of the prediction is that the industry grows faster because neighboring 
firms learn from each other.  The data and analysis presented in this research demonstrate the 
existence of clusters within these sectors in the Colorado and North Carolina study areas.  This 
demonstrates the benefits of life science industry cluster formation within regions. 
2.2.1  Spatial Concentrations: Cluster Development Strategy 
Almost every state has a cluster development strategy as part of its economic 
development plan.  The Brookings Institute reported in 2002 that 41 communities were pursuing 
a life science cluster strategy even though 75% of the largest biopharmaceutical firms are located 
in only nine regions of the United States (St.John and Pouder 2006).  Firms within certain sectors 
of the life science industry are often very successful when spatially concentrated.  A firms‟ 
specific industry classification affects what type of interactions are created within clusters.  
Biopharmaceutical industry clusters are characterized by an analytical and science-based 
knowledge base related to natural sciences like biology, chemistry, and medicine (Coenen et al. 
2006).  The agro – food industry is more synthetic and engineering-based involving food 
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technology, agriculture, and basic knowledge transfer between agro-food companies and large 
public research institutes.  The pharmaceutical sector is the largest niche in terms of amount of 
sales, accounting for over 70% of all sales in life sciences.  The biopharmaceutical industry is 
based on R&D trade among universities, research institutes, pharmaceutical companies, and small 
life science firms.  
Biopharmaceutical businesses in the United States thrive in geographic clusters, 
attracting capital investment and facilitating technology transfer.  Highly skilled labor tends to be 
more concentrated in some MAs than others.  A major factor in the development of a cluster is a 
nearby research university, which is necessary because of the need to remain competitive and 
have access to the latest technological innovations in this knowledge-based industry (Walcott 
2002). Life science firms tend to concentrate geographically around research universities and 
health centers.  Marshall developed the notion of “industrial districts” as aggolmerations of firms 
operating in one industry sector in a well-defined and relatively small geographic area (St. John 
and Pouder 2006).  Other innovative models include innovative milieus and technology districts. 
Cluster formation and evolultion could be the result of various factors including start-up firms 
evolving or just proximity to a large customer base or market.   
Some of the numerous advantages of firms in clusters include cost savings, increased 
market power, availability of specialized labor facilities, sharing of information, proximity to 
suppliers or markets, learning, innovation, and increased specialization (Feser and Luger 2003).  
Clusters have been used by policy-makers, community leaders, and citizens to understand the 
complexity of regional economies.  Biotechnology is considered a “hot cluster” along with the 
fields of bioinformatics and information technology.   Policy-makers are generally more 
interested in emerging and potential high-tech clusters because they provide good jobs and are 
beneficial for regional economic analysis.  Although cluster studies are useful,  they must have 
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clearly laid-out goals, objectives, defenitions, indicators, weghts, data sources, and models. 
Biases should also be discussed up front (Feser and Luger 2003).  These types of analyses can 
help with disagreements between local officials and the public regarding a region‟s future and 
economic prospects.   Successful development of a high-technology cluster depends on several 
factors such as a strong scientific base, government support, a highly educated workforce, and a 
good quality of life, just to name a few.  This study examines whether these factors exist in the 
metropolitan areas of the Triad/Triangle, NC and Denver/Boulder, CO.   
2.2.2  Knowledge Flows  
 R&D spillovers have a significant effect on high technology employment.  
Communication can be improved with an increase in informal relationships and more frequent 
face to face contact.  A concentration of an industry in a city can result in knowledge spillovers 
between firms and a growth of the industry (Acs, FitzRoy, and Smith 2002).  Knowledge 
spillovers are „knowledge externalities bounded in space‟, which allows companies located 
nearby important knowledge sources to introduce innovations at a faster rate than rival firms 
located elsewhere.  Firms may seek external knowledge indirectly and informally by localized 
knowledge spilling across organizational boundaries (Breschi and Lisson 2001).   
Location is key in increasing exposure to potential knowledge spillovers.  Location 
decisions often made by firms to maximize the effect of knowledge spillovers and to enhance 
their competitive position (Alcacer and Chung 2007).  Many firms strategically choose locations 
in order to more easily gain knowledge from others but also to reduce leakage of their own 
knowledge.  Generally, public sources like academia and government provide basic knowledge 
while private industry sources provide less basic, more appropriable knowledge.  Firms can serve 
as potential knowledge sources while also receiving knowledge spillovers.  Some locations have 
greater amounts of knowledge-generating activity than others.  Localized spillovers from 
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academic institutions impact the birth of biopharmaceutical companies in the United States 
(Zucker et al. 1988).   
2.3 Building a Regional Economic Growth Engine 
Employment in biopharmaceutical is expected to grow faster than employment in the rest 
of the economy through at least 2012, according to the Bureau of Labor Statistics.  Some regions 
are “hubs for organizational creation” due to a diversity of organizations, a well-established 
knowledge base (university system), law firms specializing in intellectual property, public 
research institutes, consultants, and venture capitalists (Powell, Koput and Smith-Doerr  2002).  
Private sector investment in product development is a critical factor in the development of firms 
within the biopharmaceutical industry.  Recently, public and private investment surged in bio-
related firms.  Firms spend large amounts of money on R&D for many years, thus usually 
operating at a loss.  They generally have low odds of success and developing regulatory approval 
for commercial products takes a long time.  Drugs require Federal Drug Administration (FDA) 
approval, which requires a great deal of time and money.  Venture capitalists and other investors 
often seek to recoup their investment by having the firm issue stock in an “initial public offering” 
(IPO) once promising products are developed (Cortwright and Mayer 2002).  Other sources of 
funding include R&D contracts and funding arrangements with pharmaceutical companies. 
Biopharmaceuticals is a field where firms are dependent on venture financing.  A large 
percentage of firms receive such funding from local sources.  Monitoring, advising, and 
managing are easier if the young firm is located nearby (Powell, Koput and Smith-Doerr 2002).  
Venture capitalists may play a different role in an early-stage company versus one that has 
already undergone its first round of financing.  Companies that sought only non-local finance 
were, on average, larger, older, and had more collaborations with diverse types of organizations.  
Findings also concluded that firms at the pre-initial public offering (IPO) stage with only local 
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backing were the smallest in terms of number of employees but had the largest percentage of staff 
with PhDs and/or MDs.  Locally–backed firms are generally stronger scientifically suggesting a 
strong research base.  Older, more experienced venture capital firms located in technology-rich 
areas can be more flexible in where they invest.  As they become more established and mature, 
they are more willing to work with high-risk local start-ups (Powell, Koput and Smith-Doerr 
2002).   
2.3.1  Funding 
  The founding of new biopharmaceutical  firms in the 1970s and 1980s occurred in areas 
with high “intellectual capital” (Powell, Koput and Smith-Doerr 2002).  “Star scientists” who had 
direct roles as founders and advisors resulted in closer links being established. A major source of 
funding for small biopharmaceutical firms is a R&D contract or equity funding arrangement with 
a major company.  The dollar amount of research agreements has increased from $846 million 
prior to 1990 to $5.2 billion since 1996.  As stated by Cortwright and Mayer (2002: 23) “The 
flow of research contracts from pharmaceutical funds to biotechnology firms is a strong indicator 
of the location of commercially promising research activities” .   
The availability of capital is a major factor in the development of firms within the 
biopharmaceutical industry.  Start-up firms depend heavily on venture capital investment for 
initial costs and organized venture capital is the most important source of start-up capital.  An 
example of this is a private investment made by a professional fund manager.  Venture capitalists 
may invest in several biopharmaceutical firms while firms may obtain funding from several 
venture sources.  Venture capital firms and capitalists themselves tend to be highly concetrated 
regionally. These investments are needed to sustain biopharmaceutical firms from inception 
through years of research and product development.  Technology-based startups with a high 
potential for growth are more likely to be sought after by venture capital firms.  In the case of 
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biopharmaceutical, venture capitalists may play more of a role in a financed company possiby 
even helping run the company.  This is another reason for clustering and close proximity.  The 
Colorado and North Carolina sections of the literature review describe sources of funding for 
start-up businesses and several initiatives taking place in both states to assist in growth of the 
industry. 
2.3.2 Research and Educational Facilities 
The life science sector of the economy is very research-oriented and innovative.  
Examining the location of research institutions and universities is the first step in understanding 
the geography of biotechnology (Cortwright and Mayer 2002).  Levels of commitment to R&D 
vary among individual firms.  State governments tend to invest funds in developing 
biopharmaceutical around public research universities.  There is difficulty in the long-term 
survival of small firms without strong relationships with universities or other large 
biopharmaceutical (pharmaceutical and other) companies.  Universities are generally good 
sources of knowledge, funds, and credibility of a firm‟s reputation.  Most large public and private 
universities have invested in technology transfer in the biomedical sciences industry (Bagchi-Sen 
2007).  Universities are used for assisting in advancing research-based innovation and are 
important in terms of technology resources and access to physical resources.  Detailed 
information on the life science fields of study offered at the various research institutions within 
Colorado and North Carolina are described in this study. 
Research parks normally utilize a partnership of government, academia, and industry and 
consist of master planned land and buildings which are designed for public and private research 
(Rosenblum 2004).  A variety of activities are able to take place simultaneously including applied 
research, technology transfer and corporate research and development.  Space is provided for 
start-up firms to become established businesses and some parks provide incubator facilities.  
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University technology transfer programs are found to be a good source of business startups and 
an interface between academic research and industry.  Regional and state governments view 
research parks as great economic development tools.  Universities generally seek business 
opportunities for students, training, and increased technology transfer while private industry 
attempts to develop clusters of like-mined businesses.   
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CHAPTER III 
 
RESEARCH DESIGN 
 
 
This research will demonstrate the economic strength of the life science industry in the 
selected metropolitan regions in Colorado and North Carolina.  It will also show the different 
specializations existent in each proximate place, and location factors of individual firms.  The 
important factors of proximity, commuting ties, industry clusters, and funding will be examined 
by utilizing data from various sources.  Research funding and grant statistics are obtained from 
the National Institute of Health (NIH) to show the amount received by the top universities within 
the study areas.  Commuting pattern statistics are obtained from the U.S. Census Bureau, Census 
Transportation Planning Package (CTPP) to demonstrate the amount of workers traveling daily 
between the selected MSAs and CSAs.  This will emphasize the importance of geographic 
proximity in maintaining a region‟s economic strength.  Industry clusters are determined by 
computing the number of employees from the Bureau of Labor Statistics (BLS) and 
ReferenceUSA Company database to visualize total number of employees and employment 
concentration within select industry classifications.  
The nature of the industrial employment clusters and location of research-intensive 
universities will prove that the key proximate metropolitan areas are complementary regions.  The 
analysis presented will show how proximate places are able to benefit from each other and work 
together in building a strong regional economy.  It contributes to the idea that the 
biopharmaceutical industry is highly sought after as a tool for regional economic strength and has 
the ability to unify metropolitan regions.
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3.1 Study Area 
Colorado and North Carolina contain metropolitan regions in which spatial 
concentrations of sectors within the biopharmaceutical industry thrive.  Life science sector firms 
are very profitable and have a beneficial impact on the regions in which they are located.  This 
research asserts that metropolitan areas within close proximity of each other are able to share the 
benefits of economic development within this sector.  Both states contain two proximate, 
complimentary regions which share benefits of interactions within the life science sector.  
Remember that a region is defined here as an MSA or CSA.  In Colorado, the proximate MSAs of 
Boulder and Denver are examined.  The Greeley MSA will also be included since it is part of the 
same CSA.  The North Carolina study area is different from Colorado in that two proximate 
CSAs are examined: Greensboro – Winston-Salem – High Point (referred to as the Triad), and 
Raleigh – Durham – Cary (referred to as the Triangle).  The Colorado study area is shown in 
Figure 3.1 and North Carolina‟s in Figure 3.2.  Compiled data include research grant funding, 
commuting patterns within each region, total available employment figures, and opinions 
expressed through individual company surveys.  
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Figure 3.1 
 
Figure 3.2 
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These study regions were chosen because of their high ranking in terms of life science 
employment.  The Brookings Institution classifies the Raleigh – Durham – Chapel Hill MSA as a 
biotechnology center, meaning it has an above average level of research activity and 
commercialization.  The Denver – Boulder – Greeley and Greensboro – Winston-Salem – High 
Point MSAs are classified as median metropolitan areas (Cortwright and Mayer 2002).  This 
study used 1997 MSA definitions.  According to 2003 BLS data, the Boulder MSA ranked 
number one in terms of its location quotient (LQ) statistic which measures employment 
concentration within the research and development  and pharmaceutical and medicine 
manufacturing sectors.  The Raleigh – Durham – Chapel Hill MSA ranked 3rd, Denver - Aurora 
27
th
, and Greensboro – Winston-Salem, High Point 34
th
 (Debbage and Nuyda 2005).  These are 
based on a study of 40 MSAs using 1999 definitions.  Each study region contains one highly 
ranked region adjacent to one which is ranked lower, in terms of life science employment.  It is 
believed that metropolitan areas within close proximity of each other are able to share the benefits 
of economic development within a particular economic sector.   
3.2 Research Facilities and Funding 
The largest single source of funding for research and training related to medicine, health, 
and biopharmaceutical is the National Institute of Health (NIH).  To demonstrate the strength of 
the life science research base in the study areas, the amount of research grant funding and the 
national ranking of the major universities are presented in the Analysis section.  NIH data were 
obtained from the U.S. Department of Health and Human Services, Office of Extramural 
Research.  General information on academic programs related to life sciences is also presented, 
along with maps showing university locations. 
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3.3 Commuting Between Proximate Places    
Commuting pattern statistics were compiled from the Journey to Work and Place of 
Work section of the U.S. Census Bureau Transportation Planning Package.  Although the data 
represent all workers, not just life science employees, the statistics show the amount of 
commuting taking place between the MAs and CSAs to demonstrate the general traits of a 
regional growth engine and the connection between proximate places.  Even though CSAs are 
defined by the U.S. Census Bureau as an aggregate of adjacent MSAs that are linked by 
commuting ties, it is beneficial to look at commuting statistics, especially noting the amount of 
commuting taking place between the selected proximate regions (U.S. Census Bureau 2008).  
Data were collected as “Residence to Workplace”, showing the number of daily commuters from 
one county to another.  This was done for each county to each other county in the study regions. 
The total number of daily commuters between the proximate MSAs and CSAs was then 
calculated.   
3.4 Life Science Sectors and Employment 
 The North American Industry Classification System (NAICS) is defined by the Office of 
Management and Budget of the federal government and classifies industry nationwide 
(Cortwright and Mayer 2002).  According to the Brookings Institution (2002), most life science 
firms fall into either of two industry categories: 54171 – Research and Development in Physical, 
Engineering, and Life Sciences or 32541 – Pharmaceutical and Medicine Manufacturing, but 
there is no one generally accepted definition of biotechnology (Debbage and Nuyda 2005).  This 
report will define the life science sector by the following nine NAICS codes as defined by the 
Census, to cover the broad range of related activities that take place within the sector: 
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a) 325411: Medicinal and Botanical Manufacturing 
b) 325412: Pharmaceutical Preparation Manufacturing 
c) 325413: In-Vitro Diagnostic Substance Manufacturing 
d) 325414: Biological Product (except Diagnostic) Manufacturing 
e) 334510: Electro medical and Electrotherapeutic Apparatus Manufacturing 
f) 334517: Irradiation Apparatus Manufacturing 
g) 339111: Laboratory Apparatus and Furniture Manufacturing 
h) 339112: Surgical and Medical Instrument Manufacturing 
i) 541710: Research and Development in Physical, Engineering, and Life Sciences 
 
These codes encompass a variety of life science drug and pharmaceuticals and manufacturing 
activities that take place along with research and development.  Batelle (2006) includes these 
NAICS codes in his analysis.  Since defining life sciences is difficult, he identified four major 
subsectors: Agricultural Feedstock and Chemicals, Drugs and Pharmaceuticals, Medical Devices 
and Equipment, and Research, Testing, and Medical Laboratories.  This study will not include 
analysis of Agricultural Feedstock and Chemicals.  The nine codes chosen here fall into one of 
the latter three categories.  The selected study regions in both Colorado and North Carolina 
contain a great number of firms within these categories.   
Employment data were compiled from the U.S. Department of Labor – Bureau of Labor 
Statistics (BLS) and the ReferenceUSA business database for the years 2006 and 2007.  The BLS 
proved useful for total number of employees for the study areas.  This statistic was used in the 
equation for location quotients (LQ), described later in this section.  Total employment within 
each sector was calculated using the available individual company information downloaded from 
the ReferenceUSA database.  An identification and password is required and was accessed 
through the University of North Carolina – Greensboro online library system.  Data provided 
through the database is updated monthly.  This research utilized August 2007 data.  The selection 
criteria used was NAICS code within the counties located within the specified MSAs.  Data were 
downloaded from two business databases: U.S. Businesses, and Corp Tech.  The U.S. Business 
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database includes a broad range of sectors of employment while the Corp Tech database lists 
companies specializing in biopharmaceutical, computer hardware/software, and pharmaceuticals.   
One important difference between the two databases is that the U.S. Business database provides 
latitude and longitude information while the Corp Tech database does not provide this 
information.   
The Analysis section of this research will show maps of company locations by NAICS 
code, using the U.S. Business list, while the Corp Tech companies are in a list.  Available data 
includes the total number of employees and NAICS code for each company listed.  Companies 
within the selected life science NAICS codes were selected and grouped for analysis, although 
data were not available for a small number of the companies.  This data provides evidence of 
different patterns of industrial concentrations.   
The employment statistics, along with calculated LQs for each county within the study 
areas, provide evidence of the different specializations prominent in the different MSAs.  LQs are 
beneficial for visualizing the location of labor markets by county or region with a higher or lower 
proportion of their employment base in life sciences relative to a national norm (Debbage and 
Nuyda 2005).  The equation is a ratio defined as: 
(County/Regional Biotech Employment/U.S. Biotech Employment) 
         (County/Regional Total Employment/U.S. Total Employment) 
A LQ greater than one indicates an area with a higher percentage of biotech employment than the 
percentage of total jobs relative to a national share while an LQ less than one indicates a lower 
percentage.  
 
 
22 
 
3.5 Company Surveys 
Surveys were mailed to life science companies within the North Carolina study regions to 
gain a better understanding of local and nonlocal connections of companies and location factors 
that increase competitiveness.  The survey was created by Dr. Susan Walcott and Dr. Sharmistha 
Bagchi-Sen for another life science related study for companies in New York and North Carolina.  
The companies chosen to answer surveys were based on the North Carolina list of 414 obtained 
from the ReferenceUSA database.  The first section of the survey contained questions related to 
company background.   The respondents were asked to choose from Diagnostic, Therapeutic, 
Agri-Bio, Environment, or Other as the firm‟s main area of business.  Other background 
information obtained includes whether the company is a subsidiary of a larger firm or a university 
spin off, public or private, year established, total revenue, percent of revenue assigned to R&D, 
and how much exporting is taking place.  The second section of the survey pertains to location 
factors.  Respondents were asked top reasons for choosing their location, the most important 
forms of local/state government assistance received, and status of labor supply in the location.  
The third section presents questions related to collaborative efforts.  They were used to determine 
how much R & D activity is performed in-house and where, if any, university and industry 
collaborators are located.  The next section of questions helped gather information related to 
where, if any, company manufacturing activities take place.  The last section of the survey deals 
with innovation.  Respondents were asked to rank the importance of various innovation strategies.  
The survey is presented in Appendix A.   
 
 
23 
 
CHAPTER IV 
FINDINGS 
 
 
4.1 Education and Research 
 This section will demonstrate the strength of the research base in Colorado and North 
Carolina, contributing to the first thesis hypothesis that synergies among sectors within the life 
science industry exist between proximate places to build a regional economic growth engine.  
Since the life science sector of the economy is very research-oriented and innovative, examining 
the location of research institutions and universities is the first step in understanding the 
geography of biopharmaceuticals.  The quality of medical research and education available 
affects economic development of the life science industry (Cortwright and Mayer 2002).  
Universities are generally good sources of knowledge, funds, and credibility of a firm‟s 
reputation.  This section of the findings will provide a general description of the universities in 
the study areas and how much NIH funding is made available. 
4.1.1 Colorado Universities and Research Facilities 
The Denver/Boulder area is a „stand-alone‟ profit center with product related R & D 
activities employing skilled and semi-skilled workers (Lyons 1995).  The National Science 
Foundation reported 52 life science PhDs issued in 1999 by universities in the Denver-Boulder-
Greeley Metropolitan Statistical Area (MSA).  Colorado maintains a healthy link between 
academia and the private sector.  The University of Colorado system contains substantial research 
centers which support the life science industry.  The Colorado Alliance for Bioengineering is 
responsible for the coordination of biopharmaceutical activities among faculty in all universities 
throughout the state (Colorado Bioscience Association).  The University of Colorado at Denver
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and Health Services Center offer a Ph.D in Health and Behavioral Sciences, an M.S. in Health 
Administration, an M.S. in Biology, and in Chemistry.  The University of Denver offers an M.S. 
and Ph.D in Biological Sciences and PhDs in Biochemistry and Chemistry.  The University of 
Colorado at Boulder offers several PhDs including Biological Sciences (Ecology, Evolutionary, 
Molecular, Cellular, and Developmental), Chemical and Biological Engineering, and 
Biochemistry.  Other advanced degrees in Environmental Engineering and Neuroscience are also 
available. Bio-technician training is offered at the Community College of Aurora where students 
can emphasize in R&D or biotechnology manufacturing.  The Institute for Bio-Energetics was 
created by the University of Colorado – Colorado Springs to study cellular metabolism and 
communication to help treat and/or cure serious diseases.  Figure 4.1 shows the Colorado 
universities which ranked highly in research grant funding received from the NIH. 
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Figure 4.1 
 
 
 
4.1.2 North Carolina Universities and Research Facilities 
  4.1.2a Triad 
The Triad region includes the cities of Greensboro, Winston-Salem, and High Point and 
is home to several research institutions offering degrees related to life sciences.  UNC-
Greensboro offers M.S. degrees in Chemistry and Biochemistry Information, Genetic Counseling, 
and Biology.  Ph.D degrees are available in Nutrition and Public Health.  NC A&T State 
University offers an M.S. degree in Biology, a Ph.D in Energy and Environmental Studies, and an 
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undergraduate degree in Chemistry.  Both of these universities are in the process of developing a 
joint graduate program in nanoscience and nanoengineering to be housed at the new 
Nanotechnology School and Gateway University Research Park.  The Joint School of 
Nanoscience and Nanoengineering (JSNN) will enroll Masters and Doctorate students focusing in 
nanotechnology research.  High Point University offers undergraduate degrees in biology, 
chemistry, and medical technology.  Another major Triad university is Wake Forest (and the 
Bowman Gray School of Medicine) located in Winston-Salem.  Along with advanced degrees in 
the field of medicine, they offer PhD‟s in Biochemistry, Structural Biology, Biomedical 
Engineering, Cancer Biology, Chemistry, Neuroscience, Physiology, and Pharmacology.  Wake 
Forest is also home to various health science departments, the Institute for Regenerative 
Medicine, and the Center for Nanotechnology and Molecular Materials.  
4.1.2b Triangle 
The Triangle region includes the cities of Raleigh, Durham, Chapel Hill, and Cary.  
Universities in this region have a great deal to offer in terms of advanced degrees in medicine and 
life science-related fields of study.  NC State University in Raleigh offers several degrees and 
certificates directly related to life sciences.  These include minor studies in Biotechnology and 
Life Science Ethics, Masters degrees in Microbial Biotechnology and Comparative Biomedical 
Sciences, and a Ph.D degree in Biomedical Engineering.  Others include PhD‟s in Biochemistry, 
Bioinformatics, Microbiology, and Biological and Agricultural Engineering.  UNC-Chapel Hill is 
home to one of the Triangle‟s medical schools.  Some of the advanced degrees are Biochemistry 
and Biophysics, Biological and Biomedical Sciences, Cell and Developmental Biology, 
Neurobiology, and Pharmaceutical Sciences.  Duke University in Durham houses the other 
medical school in the Triangle.  It offers certificates in Biomolecular and Tissue Engineering and 
Nanoscience, along with Ph.D. degrees in branches of Biology and Chemistry.  Figure 4.2 shows 
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the North Carolina universities which ranked highly in grant funding from the NIH.  A higher 
education bond approved in North Carolina in the year 2000 included bioscience research 
buildings like the College of Veterinary Research Building on NC State‟s Centennial Biomedical 
Campus.  Bond funding has also been approved for a new research and clinical facility at the 
UNC Chapel Hill Cancer Center budgeted at $180 million (Batelle 2006).  The Centennial 
Campus of NC State is being developed as a dual-use research park including university 
resources in genomics and bio-informatics. 
  
Figure 4.2 
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4.1.3 Research Funding 
   In 2000, NIH disbursed a total of $13.3 billion for research activities.  The Denver-
Boulder-Greeley MSA was allocated $208,884,942, a 1.8% share of the total funding to the top 
100 cities.  The share of NIH research funding for medical schools and research institutions 
increased by 0.5% between 1985 and 2000 – from $29,698,000 to $134,378,000 (more than 
quadrupled).  This type of funding comprises the largest share of NIH funding.  Total federal 
research funding for medical schools in all the metropolitan areas more than tripled in 15 years 
from $2.4 billion in 1985 to $7.6 billion in 2000 (Cortwright and Mayer 2002).   Research 
institutions provide highly trained and skilled scientists, many of which are financed by NIH 
grant funding.  Several institutions within the Colorado and North Carolina study areas ranked 
highly in the amount of funding awarded.  For the fiscal year 2005, 3419 institutions received 
awards.  Table 4.1 provides a listing of the major universities with their respective rankings, 
number of awards and amounts from the top 500 list. 
 
Table 4.1 Top-ranked NIH-funded Universities within the Colorado and North Carolina Study 
Areas 
 
 
Source: U.S. Department of Health and Human Services, Office of Extramural Research – NIH 
 
Among these universities, the total amount of funding for North Carolina universities is 
$834,770,648 while those in Colorado received a total of $280,701,234.  Duke in Durham, NC, 
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ranked sixth, is the highest ranking among the universities in both study areas.  This is followed 
by UNC-Chapel Hill (16
th
) and UC-Denver (30
th
).  The University of Denver ranked 451
st
, 
receiving the lowest amount among those on this list.  Nearly each major city within the study 
clusters houses a major university ranked highly in NIH funding.  In Colorado, a university from 
the list is located in Denver, Aurora, Boulder, and Fort Collins.  In North Carolina, they are 
located in the Triad city of Winston-Salem and the Triangle cities of Raleigh, Durham (two 
universities), and Chapel Hill.  The locations of these universities and the high amount of health-
related research funding provide evidence of the strength of research activities within the study 
regions.  
4.2 Business and Technological Development 
 4.2.1 Colorado 
Four bills introduced in the 2006 legislative session would benefit Colorado‟s bioscience 
industry.  The Bioscience Net Operating Loss Bill gives permission to the Colorado Economic 
Development Commission to purchase the right to gain a future tax benefit from net operating 
losses from bioscience companies.  It establishes criteria for a company to be able to sell the 
future tax benefit to the commission.  A second bill concerns the advancement of new bioscience 
discoveries at Colorado research institutions.  It provides for matching funds to support the 
development of life science technologies come from new discoveries within institutions.  A third 
bill subsidizes the indirect cost portion of contract for core laboratory services at research 
institutions by Colorado bioscience companies.   Companies would gain incentives to contract for 
services with research institutions and the research institutions would likewise be provided 
incentives to provide business-friendly services.  The fourth piece of legislation would provide a 
performance-based incentive to employers who create a certain number of new full-time jobs.  
The Office of Economic Development and International Trade works with Colorado businesses, 
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associations, and universities to encourage growth and development of life science companies.  
The Advance Colorado Center (ACC) provides a common headquarters and support for non-
profit organizations.  The organizations, in turn, provide a variety of services and programs to 
companies and entrepreneurs to enhance job growth.  The ACC is a partnership between the 
Colorado Economic Development Commission, the Office of Economic Development and 
International Trade, and the University of Colorado at Denver Health Sciences Center (Batelle 
2006).   
 An Action Plan to Grow Colorado’s Bioscience Cluster was developed in 2003 by the 
Colorado Office of Innovation and Technology, industry, university, and government 
representatives.  The idea behind the plan is that the state nurture local businesses and focus 
heavily on excelling in bioscience research.  The Action Plan is updated yearly and has resulted 
in a great deal of concentration in the northern part of the state.  The medical campus at 
Fitzsimons is home to many relocated facilities including the University of Colorado Health 
Science Center (UCHSC), the University of Colorado Hospital (UCH), and the Children‟s 
Hospital.  Approximately $53 million has been appropriated by Congress for the relocation of 
Denver‟s Veterans Affairs Hospital.  The initial phase of the full campus move is estimated to 
cost $1.3 billion.  The new location will increase from 2.7 million square feet on 46 acres to 3.4 
million square feet on 210 acres at the new location.  Another 1.5 million square feet for research 
activities is planned after the initial phase.  A total capital investment of around $4 billion will be 
required to complete the entire Fitzsimons building program.  Other projects that have been 
completed since 2004 or are under construction include two research complexes, Barbara Davis 
Center for Childhood Diabetes, Denison Library, 3 education facilities, an academic office, and a 
common area including a residential and commercial complex (Batelle 2006).  
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The U.S. Department of Labor gave the Denver metropolitan region a five - year, $15 
million Workforce Innovations in Regional Economic Development (WIRED) grant for 
workforce development and the biosciences are one of the targeted industries.  The Fitzsimons 
BioBusiness Incubator helps promote the growth and success of the bioscience businesses in 
Colorado, with an emphasis on forming a cluster at Fitzsimons.  Services include business 
planning, management, intellectual property protection, scientific resources, access to laboratory 
space, and capital formation (Batelle 2006).  The Colorado Economic Development Commission, 
Aurora Economic Development Council, Fitzsimons Redevelopment Authority, University of 
Colorado, and the Metro Denver Economic Development Corporation are some of the 
contributors.  The Colorado Venture Capital Authority (VCA) was created in March 2004 
because of legislation signed by the Governor.  The legislation requires that the funds be used to 
provide capital in early stages of company development.   
The Colorado Bioscience Park Aurora is being developed as a part of the Fitzsimons 
Redevelopment Project.  The park is affiliated with the University of Colorado and is expected to 
contain 3 million square feet of space and 4000 employees.  Research-oriented biomedical, 
biotechnology, and pharmaceutical facilities will be a large part of the park‟s development 
process.  The Bioscience Park Center opened in 2000 and currently houses 18 bioscience 
companies taking advantage of specialized equipment and facilities (Batelle 2006).  Denver 
Bioscience Center at Stapleton is under development at the former Stapleton Airport and will 
consist of a 200-acre biomanufacturing park.  It will provide space for small spin-offs to expand 
their manufacturing operations and is in close proximity to the Colorado Bioscience Park at 
Fitzsimons.   
The Fitzsimons Redevelopment Authority in Aurora is a $ 4.3 billion life sciences 
complex that has become the focus of the biopharmaceutical industry in the Rocky Mountain 
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region (Krizner 2005).  It lies on the site of a former U.S. Army medical base, which has assumed 
control of 332 acres, while the University of Colorado controls the rest.  Currently, 5000 people 
are employed there, and that is expected to grow to 19,000 by 2010.  Funding has been approved 
by the Colorado state legislature for the university to build a Health Sciences Center on a 217-
acre site by 2008.  The complex will include the university‟s education and research buildings 
and a medical library.  One hundred sixty acres is designated as the Colorado Bioscience Park – 
Aurora which including an incubator.  Companies need three qualifications to join the incubator 
program: 1) research needs to be in life sciences, 2) science has to be peer-reviewed, and 3) there 
needs to be a compelling reason to be in the incubator program.  Officials at Fitzsimons will 
consider whether a technology has the opportunity to grow a company (Krizner 2005). 
According to PriceWaterhouseCoopers Moneytree and IPO.com, 16 venture capital 
investments were made in the Denver-Boulder-Greeley CMSA between 1995 and 2001, totaling 
$156,162,000 or a 1.6% share of the total venture capital investments made during this time in the 
United States.  The Commercial Opportunity Fund was created by Colorado State University to 
support early feasibility studies and analyses of technologies that may emerge from its faculty.  
The fund‟s purpose is to provide monetary support to increase the likelihood of commercial 
success of the technologies.  Criteria used by the Colorado State University Research Foundation 
(CSURF) to grant awards include commercial viability, proximity to completion, market 
research, and adequacy (Batelle 2006).  The Proof of Concept (POC) Fund, created by the 
University of Colorado, is similar to Commercial Opportunity Fund but uses a competitive 
application process managed by the Technology Transfer Office.  Recombinant Capital is a 
private analyst of the biopharmaceutical industry and reports the dollar value of R&D.  The total 
value for Denver-Boulder-Greeley between 1990 and 2001 was $169 million which increased 
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from $19 million prior to 1980 to $133 million between 1996 and 2001 (Cortwright and Mayer 
2002).    
4.2.2 North Carolina 
Many regions across America are developing strategies to create and grow clusters of 
biopharmaceutical companies, and many are cultivating in the Triangle and Piedmont Triad 
(Batelle 2006).  These regions are working to replace jobs in older, declining, and manufacturing 
industries with life sciences since it is a field that can compete in national and international 
markets.  Clusters and concentrations of businesses are an important requirement for the success 
of the industry in these two metropolitan areas.  Many regional policy-makers invest in R&D 
infrastructure to help sustain university-industry connections.  Alliances and access to knowledge 
may not necessarily be bound by geography but spatial proximity promotes vital knowledge 
spillovers.  North Carolina experienced a decline in the textile, apparel, furniture, and tobacco 
industries because the state lacked a strong R&D base.  This prompted an effort to shift policy 
from traditional manufacturing to high-tech businesses.  Government leaders and policy-makers 
believe that the state should nurture the identified existing clusters of high-growth and R&D-
intensive activity.  Stressing the development of these clusters will help achieve and maintain a 
competitive advantage (Feser and Luger 2003). 
 Strategies implemented to expand the industry throughout the state include the New Jobs 
Across North Carolina policy developed in 2004 by the North Carolina Biotechnology Center.  
The nonprofit Golden LEAF Foundation contributed to the $60 million Biomanufacturing and 
Pharmaceutical Training Consortium, a network created through NC State University, Central 
University in Durham, and the NC Community College System.  This fund also contributed a 
great deal to a bioscience venture fund.  The Biotechnology Center offers institutional 
development and multidisciplinary research grants or bioscience research at North Carolina 
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universities.  The Center, along with the UNC system, provides a trust fund and other sources for 
assistance in faculty recruitment.  Collaborative funding grants are offered by the Biotechnology 
Center and the Kenan Institute for Engineering, Technology and Science at NC State to match 
university and industry contributions to joint research projects (Batelle 2006).   
The North Carolina Small Business and Technology Development Center offers grants 
for universities participating in applied research that are matched by in-state companies.  The 
Council for Entrepreneurial Development is a non-profit organization that mentors and prepares 
entrepreneurs in the Research Triangle area for raising venture capital.  The Biotechnology 
Center also makes loans to companies for product development, proof-of-concept research and 
business planning (Batelle 2006).  There are several bioscience incubators available in North 
Carolina including a 14,000-square-foot one at the First Flight Venture Center in RTP, RTP 
BioVenture Center, and the NC State Technology Incubator.  Research Triangle Park (RTP) has 
grown since its development in the 1950s with the goal of attracting R&D labs in biosciences, 
including agricultural (Batelle 2006).  It now encompasses over 15 million square feet of office 
space on over 7000 acres.  The Piedmont-Triad Research Park in Winston-Salem currently houses 
14 bioscience companies and uses resources from Bowman Gray School of Medicine at Wake 
Forest University.   
 Parks provide “a nurturing environment in which to work” as a full-fledged stand-alone 
business (Krizner 2005: 16).  The biggest challenge to startup a company is often the transition 
from the academic world to the business world.  Biopharmaceutical economic development 
projects grew tremendously during the past few years. The industry is constantly finding new 
products and vaccines while maintaining job growth.  
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4.3 Commuting Patterns 
CSAs are defined by the U.S. Census Bureau as an aggregate of adjacent MSAs that are 
linked by commuting ties (U.S. Census Bureau 2008).  Included in this research are the 
commuting statistics, especially to note the amount of commuting taking place between the 
selected proximate regions (MSAs or CSAs).  Tables 4.2 and 4.3 show the number of commuters 
traveling daily between the counties of the Colorado and North Carolina study regions.   
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From these figures, the following number of commuters between proximate regions was 
determined: 
Location      Number of Commuters 
 
Boulder MSA to Denver-Aurora MSA    26,386 
Boulder MSA to Greeley MSA       2,419 
Denver Aurora MSA to Boulder MSA    39,118 
Denver-Aurora MSA to Greeley MSA       2,209  
Greeley MSA to Boulder MSA        7,771 
Greeley MSA to Denver-Aurora MSA     10,962 
Greensboro – Winston-Salem – High Point CSA  
to Raleigh – Durham – Cary CSA   11,052 
Raleigh – Durham – Cary CSA to  
Greensboro – Winston-Salem – High Point CSA  7,177 
 
This data helps demonstrate the interaction between the proximate places in each state and 
contributes to the hypothesis that synergies exist. 
4.4   Employment 
 Tables 4.4 and 4.5 show the numbers of employees and LQs by NAICS code for the 
counties in the Colorado and North Carolina study areas.  After data were collected from the 
ReferenceUSA database, very few employees from both study areas were listed for NAICS 
334517 (Irradiation Apparatus Manufacturing), so it was left out of the LQ calculation.  LQ is 
used in this analysis as an indicator of the strength of the employment bases of the specified life 
science sectors.  Table 4.4 shows that Boulder County (also its own MSA) has the highest LQ in 
biological product manufacturing, surgical and medical instrument manufacturing, and research 
and development.  Denver County shows the highest in surgical and medical instrument 
manufacturing, and the same is true for all the counties combined.  Table 4.5 shows that Durham 
County is similar to Boulder, in that the LQ is high for surgical and medical instrument 
manufacturing and research and development.  Biological product manufacturing returns the 
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highest LQ for all counties in the North Carolina study region.  Later in this section, the LQs for 
all sectors are presented for all MSAs covered in this study (Table 4.8 and 4.9).  
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Table 4.4 Number of Employees and LQs for Colorado Counties 
Employees LQ Employees LQ Employees LQ Employees LQ
Medicinal and Botanical Manufacturing (325411) 125 2.78
Pharmaceutical Preparation Manufacturing (325412) 69 0.31 39 0.09 439 1.94 117 0.17
In-Vitro Diagnostic Substance Manufacturing (325413) 35 2.22
Biological Product (except Diagnostic) Manufacturing (325414) 58 2.25 448 17.40
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) 6 0.10 14 0.24 31 0.18
Laboratory Apparatus and Furniture Manufacturing (339111) 18 1.24 20 0.46
Surgical and Medical Instrument Manufacturing (339112) 319 2.95 1529 7.08 5028 46.50 584 1.80
Research and Development in Life Sciences (541710) 250 0.47 563 0.53 1147 2.14 825 0.51
ALL NAICS 737 0.72 2256 1.11 7094 6.97 1577 0.52
Employees LQ Employees LQ Employees LQ Employees LQ Employees LQ
Medicinal and Botanical Manufacturing (325411) 125 0.56
Pharmaceutical Preparation Manufacturing (325412) 166 1.23 207 0.46 1037 0.51
In-Vitro Diagnostic Substance Manufacturing (325413) 15 0.48 50 0.32
Biological Product (except Diagnostic) Manufacturing (325414) 2 3.22 7 0.14 515 1.99
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) 3 0.03 54 0.39
Laboratory Apparatus and Furniture Manufacturing (339111) 38 0.26
Surgical and Medical Instrument Manufacturing (339112) 149 2.30 20 7.67 2771 12.80 19 0.09 10419 12.60
Research and Development in Life Sciences (541710) 114 0.36 840 0.78 67 0.06 3806 0.73
ALL NAICS 429 0.70 22 0.90 3843 1.89 86 0.04 16044 1.92
Denver
Douglas
Colorado Study Area Counties  
Number of Employees and Location Quotients by NAICS Code (According to ReferenceUSA Database)
Jefferson WeldElbert All Counties
Adams BoulderArapahoe
 
Table 4.5 Number of Employees and LQs for North Carolina Counties 
Employees LQ Employees LQ Employees LQ Employees LQ Employees LQ
Medicinal and Botanical Manufacturing (325411)
Pharmaceutical Preparation Manufacturing (325412) 2 0.02 929 4.00
In-Vitro Diagnostic Substance Manufacturing (325413)
Biological Product (except Diagnostic) Manufacturing (325414) 4 0.31 80 30.00 20 0.78
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) 73 1.24
Laboratory Apparatus and Furniture Manufacturing (339111)
Surgical and Medical Instrument Manufacturing (339112) 324 5.99 15 0.41 15 1.66 6308 58.30
Research and Development in Life Sciences (541710) 100 0.37 2 0.37 5662 10.50
ALL NAICS 430 0.96 82 1.46 15 0.04 15 0.18 12992 17.30
Employees LQ Employees LQ Employees LQ Employees LQ Employees LQ
Medicinal and Botanical Manufacturing (325411)
Pharmaceutical Preparation Manufacturing (325412) 10 0.04 1091 2.42 16 0.43 2 0.03
In-Vitro Diagnostic Substance Manufacturing (325413)
Biological Product (except Diagnostic) Manufacturing (325414) 3 0.12 1494 29.00 1204 156.00 10 1.30
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) 511 8.68
Laboratory Apparatus and Furniture Manufacturing (339111) 200 6.86
Surgical and Medical Instrument Manufacturing (339112) 191 1.77 202 0.94 40 1.23 174 5.37
Research and Development in Life Sciences (541710) 116 0.22 182 0.17 10 0.00 120 0.75
ALL NAICS 831 0.87 3169 1.56 16 0.09 1254 4.10 306 1.00
Employees LQ Employees LQ Employees LQ Employees LQ Employees LQ
Medicinal and Botanical Manufacturing (325411) 130 1.93 0 0.58
Pharmaceutical Preparation Manufacturing (325412) 3389 5.00 5439 2.40
In-Vitro Diagnostic Substance Manufacturing (325413) 195 4.13 195 0.00
Biological Product (except Diagnostic) Manufacturing (325414) 44 0.57 2859 11.10
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) 140 0.79 724 1.23
Laboratory Apparatus and Furniture Manufacturing (339111) 262 5.99 462 3.17
Surgical and Medical Instrument Manufacturing (339112) 240 5.55 8 1.52 1374 4.24 122 14.40 9013 8.19
Research and Development in Life Sciences (541710) 4055 2.52 10247 1.91
ALL NAICS 240 0.59 8 0.16 9589 3.14 122 1.54 28939 2.85
Orange
North Carolina Study Area Counties  
Number of Employees and Location Quotients by NAICS Code (According to ReferenceUSA Database)
Yadkin All CountiesRandolph Stokes Wake
Alamance Chatham Davidson Davie Durham
Forsyth Guilford Harnett Johnston
 
Source: ReferenceUSA Database 
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Figures 4.3 and 4.4 show the number of employees and locations of individual companies 
classified by NAICS code.  The point features for the companies are displayed in a geographic 
information system based on coordinates.  These maps present the companies obtained from the 
ReferenceUSA Business database, containing latitude and longitude information.  Tables 4.6 and 
4.7 list the companies from the ReferenceUSA Corp Tech database, since they contained no 
latitude and longitude information.  The maps and Corp Tech lists begin to show a general pattern 
of different sectors and employee size of individual companies within the study areas.  Figure 4.3 
shows larger companies within Surgical and Medical Instrument Manufacturing (NAICS 339112) 
in all three MSAs with more located in the Denver-Aurora MSA.  A dense concentration of R&D 
(NAICS 541710) companies is found in the Boulder MSA and many in this sector are scattered 
throughout Denver-Aurora.  Figures 4.4 and 4.5 show a similar pattern for North Carolina.  Large 
companies within Surgical and Medical Instrument Manufacturing are found in both CSAs while 
R&D is concentrated more in the Triangle.  The Triangle is also home to several large 
Pharmaceutical Preparation Manufacturing (NAICS 325412) companies as shown in Figure 4.5.   
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Figure 4.4  
 
Figure 4.5 
 
Source: ReferenceUSA Business Database 
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Table 4.6 Colorado Corp Tech Companies 
Company Name City ST NAICS1 Primary Industry Code Num of Employees Company Type
Isonics Corp. Golden CO 325411 Advanced Materials 16 Public
Animark, Inc. Aurora CO 325412 Medical 4 Private
Roche Colorado Corporation Boulder CO 325412 Pharmaceuticals 325 Subsidiary
Sirna Therapeutics Boulder CO 325412 Pharmaceuticals 77 Public
Shippert Medical Technologies Corp. Centennial CO 325412 Medical 15 Private
The Chemins Company, Inc. Colorado Springs CO 325412 Pharmaceuticals 110 Private
EAS, Inc. Golden CO 325412 Pharmaceuticals 200 Private
GTC Nutrition, LLC Golden CO 325412 Pharmaceuticals 3 Private
Ora Labs Inc Parker CO 325412 Pharmaceuticals 153 Subsidiary
Myogen, Inc. Westminster CO 325412 Pharmaceuticals 53 Public
Affinity Bioreagents, Inc. Golden CO 325413 Biotechnology 15 Private
Martek Biosciences Boulder Corporation Boulder CO 325414 Biotechnology 30 Subsidiary
Pharmion Corporation Boulder CO 325414 Pharmaceuticals 50 Public
Proligo LLC Boulder CO 325414 Biotechnology 331 Subsidiary
SomaLogic, Inc. Boulder CO 325414 Biotechnology 40 Private
AspenBio, Inc. Castle Rock CO 325414 Biotechnology 11 Public
Evolutionary Genomics, LLC Lafayette CO 325414 Biotechnology 13 Private
Geobiotics, LLC Lakewood CO 325414 Biotechnology 7 Private
GlobeImmune, Inc. Louisville CO 325414 Biotechnology 34 Private
Allos Therapeutics, Inc. Westminster CO 325414 Pharmaceuticals 57 Public
CardioOptics, Inc. Boulder CO 334510 Medical 12 Private
Encision, Inc. Boulder CO 334510 Medical 35 Public
Conmed Electrosurgery Centennial CO 334510 Medical 331 Subsidiary
Williams-Associates Inc Commerce City CO 334510 Medical 6 Unknown
Denver Instrument Co Denver CO 334510 Environmental 12 Public
VIASYS Healthcare Inc. Nicolet Vascular Inc. Golden CO 334510 Medical 3 Subsidiary
Gambro Healthcare Lakewood CO 334510 Medical 500 Subsidiary
Mesa Laboratories, Inc. Medical Division Lakewood CO 334510 Medical 32 Division
Medivance, Inc. Louisville CO 334510 Medical 35 Private
Mountain X Ray & Equipment Inc Denver CO 334517 Medical 5 Private
Sienco, Inc. Arvada CO 339111 Medical 3 Private
Scientech, Inc. Boulder CO 339111 Test & Measurement 18 Private
Vitraform Inc Denver CO 339111 Test & Measurement 20 Private
Accellent Cardiology Arvada Arvada CO 339112 Medical 140 Division
Therapeutic Recreation Systems, Inc. Boulder CO 339112 Medical 5 Private
Tyco Healthcare Group LP Valleylab Division Boulder CO 339112 Medical 664 Division
Valleylab Boulder CO 339112 Medical 1201 Division
Endo Pharmaceuticals Colorado Boulder CO 339112 Medical 21 Subsidiary
Pare Surgical Inc Centennial CO 339112 Medical 1 Private
Preferred Medical Products, Inc. Centennial CO 339112 Medical 35 Private
Certol International, LLC Cottrell Commerce City CO 339112 Medical 30 Private
Genesee BioMedical, Inc. Denver CO 339112 Medical 17 Private
Baxa Corporation Englewood CO 339112 Medical 185 Private
Denver Biomedical, Inc. Golden CO 339112 Medical 50 Private
Employee Information Services, Inc. Lakewood CO 339112 Medical 65 Private
Ferraris Medical, Inc. Louisville CO 339112 Medical 40 Subsidiary
Inverness Medical BioStar, Inc. Louisville CO 339112 Medical 300 Division
Sound Surgical Technologies LLC Louisville CO 339112 Medical 58 Private
Mc Kinley Medical LLC Wheat Ridge CO 339112 Medical 24 Private  
Source: ReferenceUSA Corp Tech Database 
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Table 4.7 North Carolina Corp Tech Companies 
Company Name City ST NAICS1 Primary Industry Code Num of Employees Company Type
Aeolus Pharmaceuticals Inc. Research Triangle Park NC 325412 Pharmaceuticals 5 Public
Apex Bioscience, Inc. Durham NC 325412 Pharmaceuticals 10 Subsidiary
Ardent Pharmaceuticals, Inc. Durham NC 325412 Pharmaceuticals 16 Private
DarPharma, Inc. Chapel Hill NC 325412 Pharmaceuticals 13 Private
EISAI Inc Research Triangle Park NC 325412 Pharmaceuticals 230 Private
Eli Lilly and Co. Sphinx Laboratories Durham NC 325412 Pharmaceuticals 148 Division
Gentris Corp. Morrisville NC 325412 Pharmaceuticals 15 Private
Gilead Sciences, Inc. Durham NC 325412 Pharmaceuticals 180 Division
IDEXX Pharmaceuticals, Inc. Greensboro NC 325412 Pharmaceuticals 40 Private
Inspire Pharmaceuticals, Inc. Durham NC 325412 Pharmaceuticals 165 Public
Krenitsky Pharmaceuticals Inc. Durham NC 325412 Pharmaceuticals 6 Private
Kucera Pharmaceutical Co., Inc. Winston Salem NC 325412 Biotechnology 5 Private
MoliChem Medicines Inc. Chapel Hill NC 325412 Pharmaceuticals 4 Private
Novo Nordisk Pharmaceutical Clayton NC 325412 Pharmaceuticals 365 Unknown
Pozen, Inc. Chapel Hill NC 325412 Pharmaceuticals 38 Public
Salix Pharmaceuticals, Ltd. Raleigh NC 325412 Pharmaceuticals 83 Public
TEAMM Pharmaceuticals, Inc. Morrisville NC 325412 Pharmaceuticals 85 Subsidiary
Targacept Inc. Winston Salem NC 325412 Pharmaceuticals 72 Private
Tranzyme, Inc. Research Triangle Park NC 325412 Pharmaceuticals 32 Private
Trimeris, Inc. Durham NC 325412 Biotechnology 100 Public
Tyco Healthcare Mallinckrodt Raleigh NC 325412 Pharmaceuticals 280 Division
Hybrizyme Corp. Raleigh NC 325413 Biotechnology 7 Private
Icoria, Inc. Morrisville NC 325413 Biotechnology 188 Public
Ajinomoto AminoScience, LLC Raleigh NC 325414 Biotechnology 130 Private
AlphaVax Human Vaccines, Inc. Research Triangle Park NC 325414 Pharmaceuticals 60 Private
Argos Therapeutics, Inc. Durham NC 325414 Pharmaceuticals 65 Private
Athenix Corp. Durham NC 325414 Biotechnology 38 Private
Biogaia Biologics, Inc. Raleigh NC 325414 Biotechnology 3 Subsidiary
Biolex, Inc. Pittsboro NC 325414 Biotechnology 80 Private
Carolina By-Products Co. Greensboro NC 325414 Biotechnology 1494 Private
EMD Pharmaceuticals, Inc. Durham NC 325414 Pharmaceuticals 166 Subsidiary
Piedmont Research Ctr Morrisville NC 325414 Biotechnology 40 Private
Serenex Durham NC 325414 Biotechnology 25 Private
Talecris Biotherapeutics, Inc. Research Triangle Park NC 325414 Biotechnology 1700 Private
Vesta Therapeutics, Inc. Durham NC 325414 Biotechnology 7 Private
Zen-Bio, Inc. Research Triangle Park NC 325414 Biotechnology 9 Private
BMG LabTechnologies, Inc. Durham NC 334510 Biotechnology 50 Private
BioStratum Inc. Durham NC 334510 Medical 23 Private
Carolina Medical, Inc. King NC 334510 Medical 11 Subsidiary
Diagnostic Healthcare Systems Raleigh NC 334510 Medical 20 Private
LipoScience, Inc. Raleigh NC 334510 Medical 120 Private
MED-EL Corporation North America Durham NC 334510 Medical 0 Subsidiary
Aeroglide Corporation Cary NC 339111 Test & Measurement 145 Private
Flexcell International Corp. Hillsborough NC 339111 Biotechnology 10 Private
Purolator Facet Inc Greensboro NC 339111 Subassemblies & Components 200 Public
Bespak, Inc. Cary NC 339112 Medical 85 Public
Hospira, Inc. Clayton Clayton NC 339112 Medical 60 Division
Innovative Devices, LLC Raleigh NC 339112 Medical 2 Partnership
MEDTOX Diagnostics, Inc. Burlington NC 339112 Medical 65 Subsidiary  
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Medi USA Whitsett NC 339112 Medical 32 Unknown
Nobex Corporation Durham NC 339112 Medical 42 Private
Owens & Minor Raleigh NC 339112 Medical 57 Unknown
Ribonomics, Inc. Durham NC 339112 Biotechnology 5 Private
STEMCO Biomedical, Inc. Durham NC 339112 Medical 26 Private
SunTech Medical, Inc. Morrisville NC 339112 Medical 70 Private
TriPath Oncology, Inc. Durham NC 339112 Medical 70 Subsidiary
Triangle Biomedical Sciences, Inc. Durham NC 339112 Medical 30 Private
bioMerieux, Inc. Durham NC 339112 Biotechnology 3850 Subsidiary
AAIPharma Inc. Analytical Services Inc. Chapel Hill NC 541710 Pharmaceuticals 58 Division
Alpha-Gamma Technologies, Inc. Research and Engineering Division Raleigh NC 541710 Environmental 0 Division
Amphora Discovery Corp. Durham NC 541710 Pharmaceuticals 56 Private
Bayer Environmental Science Clayton NC 541710 Biotechnology 22 Unknown
CaroTech, LLC Durham NC 541710 Pharmaceuticals 3 Private
Cato Research Ltd Durham NC 541710 Biotechnology 300 Subsidiary
Charles River Clinical Services Cary NC 541710 Test & Measurement 2827 Division
Chathamborough Research Group Pittsboro NC 541710 Pharmaceuticals 2 Private
Chemical Technologies, LLC Graham NC 541710 Chemicals 70 Private
Constella Group Inc. Durham NC 541710 Computer Software 170 Private
Eastern Technical Associates Raleigh NC 541710 Environmental 20 Private
Embrex, Inc. Durham NC 541710 Biotechnology 309 Public
Fortron Bio Science, Inc. Morrisville NC 541710 Biotechnology 7 Private
Health Decisions, Inc. Chapel Hill NC 541710 Biotechnology 43 Private
Honda R & D Americas Inc Haw River NC 541710 Factory Automation 30 Public
HumanCentric Technologies, Inc. Cary NC 541710 Computer Hardware 40 Private
Integrated Laboratory Systems, Inc. Durham NC 541710 Environmental 120 Private
King Pharmaceuticals Inc Cary NC 541710 Pharmaceuticals 65 Unknown
Laboratory Corporation of America Research Triangle Park NC 541710 Pharmaceuticals 700 Division
Lineberry Research Associates, LLC Research Triangle Park NC 541710 Pharmaceuticals 75 Private
MediaSpan Group, Inc. Durham NC 541710 Telecommunications & Internet 200 Private
Metabolon Inc Durham NC 541710 Factory Automation 34 Private
National Institute of Environmental Health Sciences Research Triangle Park NC 541710 Medical 1000 Subsidiary
National Institute-Environmntl Hlth Sciences Research Triangle Park NC 541710 Environmental 875 Non-profit
Norak Biosciences, Inc. Morrisville NC 541710 Biotechnology 29 Private
Novozymes North America, Inc. Franklinton NC 541710 Biotechnology 400 Subsidiary
Nuada Pharmaceuticals, Inc. Durham NC 541710 Pharmaceuticals 30 Private
PPD Discovery Morrisville NC 541710 Biotechnology 43 Subsidiary
PharmaLinkFHI, Inc. Research Triangle Park NC 541710 Pharmaceuticals 0 Private
SCYNEXIS Chemistry and Automation, Inc. Research Triangle Park NC 541710 Biotechnology 80 Private
Scientific Services Program Chapel Hill NC 541710 Biotechnology 5 Non-profit
Synthon Parmaceuticals Research Triangle Park NC 541710 Factory Automation 35 Unknown
TransTech Pharma Inc. High Point NC 541710 Biotechnology 70 Private
Valspar Corp High Point NC 541710 Advanced Materials 100 Public
inGenium research, inc. Cary NC 541710 Biotechnology 30 Private
nTouch Research Corp. Raleigh NC 541710 Pharmaceuticals 90 Private  
Source: ReferenceUSA Corp Tech Database 
  
Each MSA‟s specialization in life sciences is more apparent in Tables 4.8 and 4.9.  These 
show the calculated LQ‟s by NAICS code for each MSA.  Table 4.8 shows that surgical and 
medical instrument manufacturing is the most dominant in both Boulder and Denver-Aurora, but 
far higher in Boulder at 46.5.  This sector is considered the specialization for both of these MSAs.  
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These LQs conclude that the Boulder MSA is the hub of life science and manufacturing activities.  
The Greeley MSA does not have a significant life science industry base.   
The hypothesis that each MSA develops its own specialization is more applicable to the 
North Carolina study area.  This is evident from the LQs shown in Table 4.9.  It shows that 
biological product manufacturing is the specialization in the Triad (LQ of 11.67) while it is 
surgical and medical instrument manufacturing in the Triangle (LQ of 12.18).  The Triangle 
specializes more in R&D than the Triad.  The Triad has a higher LQ for all the other 
manufacturing activities than the Triangle, except for pharmaceutical preparation manufacturing 
and laboratory apparatus and furniture manufacturing. 
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Table 4.8 Colorado MSA LQs 
Denver-Aurora Boulder Greeley
Medicinal and Botanical Manufacturing (325411) 0.62
Pharmaceutical Preparation Manufacturing (325412) 0.29 1.94
In-Vitro Diagnostic Substance Manufacturing (325413) 0.35
Biological Product (except Diagnostic) Manufacturing (325414) 0.29 17.40
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) 0.08 0.24
Laboratory Apparatus and Furniture Manufacturing (339111) 0.15 1.24
Surgical and Medical Instrument Manufacturing (339112) 5.52 46.50 0.09
Research and Development in Life Sciences (541710) 0.54 2.14 0.06
All NAICS 0.97 6.97 0.04
MSA
Boulder/Denver, CO - Location Quotients
 
 Table 4.9 North Carolina MSA LQs 
Triad Triangle
Medicinal and Botanical Manufacturing (325411) 0.97
Pharmaceutical Preparation Manufacturing (325412) 0.98 3.20
In-Vitro Diagnostic Substance Manufacturing (325413) 2.06
Biological Product (except Diagnostic) Manufacturing (325414) 11.67 8.80
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) 1.74 0.60
Laboratory Apparatus and Furniture Manufacturing (339111) 2.75 3.00
Surgical and Medical Instrument Manufacturing (339112) 2.07 12.18
Research and Development in Life Sciences (541710) 0.15 3.06
All NAICS 0.95 4.76
CSA
Triad/Triangle, NC - Location Quotients
 
Source: ReferenceUSA Database 
 
4.5  Surveys 
The companies chosen to answer surveys were based on the North Carolina list of 414 
firms obtained from the ReferenceUSA database.  The response rate for the individual company 
surveys was low at 4% (18 respondents), but the answers provide insight into specific location 
factors of life science firms in North Carolina. Just under one-half of the companies that disclosed 
their name and location are in the Triad (Greensboro, Winston-Salem, Burlington, and Haw 
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River) while the remaining are located in the Triangle (Raleigh, Durham, and, Chapel Hill, and 
RTP).  Eleven percent of the companies are classified as diagnostic, 45 percent therapeutic, 11 
percent agri-bio, and 33 percent classified themselves in the “other” category (i.e. biodiesel and 
manufacturing).   Company names are anonymous. These results are shown in Table 4.10.   
 
Table 4.10 Company Background Information from Surveys 
Company CSA Main Area of Business Company Type Year Established Number of Employees
1 Triangle Other (biofuels) Other (company) 2003 24
2 Triad Other (biologic, scaffolding) Other 1989 8
3 Triangle Therapeutic A spin off from a university 2000 7
4 Triangle Therapeutic Other (privately held) 2003 10
5 ### Therapeutic 2001 10
6 Triangle Therapeutic A spin off from a university 2005 4
7 ### Therapeutic Other 2002 11
8 ### Agri-Bio 1994 5
9 ### Therapeutic Other (private LLC) 2001 3
10 ### Therapeutic Other 1999 100
11 Triad Diagnostic A subsidiary of a large firm 2002 4
12 Triad Agri-Bio Other (independent) 2006 2
13 Triangle Diagnostic Other 2001 5
14 Triangle Diagnostic Other (started after retiring from university) 2002 5
15 Triad Other (service) Other (small business) 1989 3
16 Triad Therapeutic Other (corporate HQ) 1955 120
17 ### Therapeutic Other 2004 12
18 Triangle Other (Bioanalytical) Other (Type "S" Corp) 1993 55   
Source: Survey created by Dr. Susan Walcott and Dr. Sharmistha Bagchi-Sen 
 
The oldest firm is a corporate headquarter therapeutic firm established in 1955. This 
company also happens to have the highest number of employees (120).  The youngest firm is an 
independent agri-bio firm established in 2006, which happens to contain the lowest number of 
employees (2).  The second largest employer is a therapeutic firm with 100 employees while a 
majority of the remaining companies employ less than ten.  All of the companies reported 
revenue earnings under $10 million with two-thirds reporting under $1 million.  The average 
percentage of total revenue assigned by a company to R&D activity is 46.5%.   Two companies 
(one therapeutic and one agri-bio) reported an assigned 100 percent of their revenue toward R&D 
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activity, although the independent agri-bio firm spent only an estimated $20,000 on R&D in the 
past 5 years.  The largest amount spent on R&D is $20 million (75% of its revenue) by a 
therapeutic company with 100 employees.   Four of the companies reported regular exporting 
activities and 13 of them do not export at all.  Table 4.11 shows these results.   
 
Table 4.11 Company Background Information from Surveys: Revenue 
Company CSA Main Area of Business Total Revenue % Revenue Estimate $ spent on Export If Yes, Revenue
for R&D R&D (past 5 yrs.) from Export, %
1 Triangle Other (biofuels) $1 - $10 million 15 750,000 no
2 Triad Other (biologic, scaffolding) $1 - $10 million 20 4,000,000 yes, regularly 30
3 Triangle Therapeutic < $1 million 75 6,000,000 no
4 Triangle Therapeutic < $1 million 40 3,000,000 no
5 ### Therapeutic < $1 million 100 yes, periodically 1
6 Triangle Therapeutic < $1 million 80 250,000 no
7 ### Therapeutic < $1 million 70 no
8 ### Agri-Bio < $1 million 20 350,000 no
9 ### Therapeutic < $1 million 50 100,000 no
10 ### Therapeutic $1 - $10 million 75 20,000,000 no
11 Triad Diagnostic $1 - $10 million 0 yes, regularly 5
12 Triad Agri-Bio < $1 million 100 20,000 no
13 Triangle Diagnostic < $1 million 75 2,250,000 yes, regularly 15
14 Triangle Diagnostic < $1 million 90 500,000 no
15 Triad Other (service) < $1 million 0 0 no
16 Triad Therapeutic $1 - $10 million 10 1,000,000 yes, regularly 30
17 ### Therapeutic < $1 million 15 750,000 no
18 Triangle Other (Bioanalytical) $1 - $10 million 3 400,000 no  
Source: Survey created by Dr. Susan Walcott and Dr. Sharmistha Bagchi-Sen 
 
Various reasons were given for the locations being chosen for establishment.  Several 
respondents noted proximity to local universities (i.e. NC State, Duke, UNC-Chapel Hill), RTP, 
Piedmont Triad Research Park, medical facilities, farms, and other firms within the industry.  A 
few personal reasons were listed such as family establishment, lifestyle, existing residence in the 
area, and new structure‟s color coordination.  A majority of the answers indicate a strong 
presence of universities, talented labor, and other biopharmaceutical firms.  It is of interest that 
two known Triad companies stated proximity to RTP as a reason for location.  This signifies the 
synergy that exists between the Triad and Triangle.  Another respondent mentioned synergies as a 
reason.  Table 4.12 lists the specific reasons given.   
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Table 4.12 Company Location Information from Surveys 
Company CSA Main Area of Business LOCATION
Reason # 1 Reason # 2
1 Triangle Other (biofuels) Good deal on buildings and land Mezzanine painted in corporate colors
2 Triad Other (biologic, scaffolding) Was already living here New opportunities have materialized in the last 3 years
3 Triangle Therapeutic Access to talented labor pool (scientists) Quality of life in RTP
4 Triangle Therapeutic talent in the area general industry player in the area
5 ### Therapeutic town zoning convenience for customers
6 Triangle Therapeutic Close to N.C. State Cost per square foot
7 ### Therapeutic biotech hub skilled worker pool
8 ### Agri-Bio proximity to markets costs
9 ### Therapeutic close to home close to Research Triangle
10 ### Therapeutic quality of life proximity to life science companies
11 Triad Diagnostic close proximity to RTP and other research groups lifestyle
12 Triad Agri-Bio close to farmers, farms close to university; industry
13 Triangle Diagnostic close to Duke and RTP important contacts in the area
14 Triangle Diagnostic established family (wife and children) in RTP area (Duke, UNC-Chapel Hill, NC State)
15 Triad Other (service) Location, near medical facilities cost factor
16 Triad Therapeutic labor costs proximity to RTP
17 ### Therapeutic already resided here research park (Piedmont Triad Research Park), synergies
18 Triangle Other (Bioanalytical) It is where I lived prior to founding the business need for labs by local industries  
Source: Survey created by Dr. Susan Walcott and Dr. Sharmistha Bagchi-Sen 
 
Eleven out of the eighteen respondents answered “No” when asked if there is a shortage 
of labor supply.  Four respondents indicated a shortage of labor supply including companies 
specializing in biofuels, therapeutic, diagnostic, and bioanalytical services.  They indicated the 
need for scientifically educated sales personnel, entrepreneurial managers, and administrative 
assistants.   
A majority of the companies do not perform R&D in-house.  All but two of the 
companies have seen an increased or the same amount of R&D collaboration with universities 
and industries in the past five years.  Less than 30% of the firms have one or more strategic 
alliances for manufacturing.  Some of the facilities are not suitable for manufacturing.  A majority 
of the companies reported developing new products and processes in the past ten years.  The 
average number of new products is approximately seven and the average number of new 
processes is three.  Most of them had only a few domestic patent approvals within this time 
period, but one company had 200.   The last section of the survey asked respondents to rank the 
importance of various innovation strategies on a scale of 1 to 5 (1 = not important, 2 = minor 
importance, 3 = moderate importance, 4 = very important, and 5 = critically important).  The 
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average score was calculated for each strategy since a wide range of scores was reported (Figure 
4.6).   
 
Figure 4.6 Survey Ranking Scores of Various Firm Innovation Strategies 
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Source: Survey created by Dr. Susan Walcott and Dr. Sharmistha Bagchi-Sen 
 
The strategies of overall highest importance are to find new domestic clients, develop new 
products on a continuous basis, and expand R&D effort.  The lowest rankings were with the 
strategies of establishing manufacturing facilities in foreign countries, aggressively seeking 
foreign investment for U.S. facilities and licensing-in technology.  The remaining strategies are 
generally at least moderately important.  All but two of the companies have seen an increased or 
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the same amount of R&D collaboration with universities and industries in the past five years.  
This tells us that firms within the region are working closely with the local universities and 
research facilities for R&D activities.  Also, a majority of the companies would like to increase 
this effort, along with finding new local clients.  This is more important to them than seeking 
foreign investment.  The overall conclusion from these survey findings is that many companies 
are likely to seek resources from within their local region.  The results contribute to the 
hypothesis that life science firms establish their locations in regional clusters and develop 
strategies for innovation and collaboration to benefit from synergies and regional growth.
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CHAPTER V 
 
CONCLUSION 
 
 
 Both Colorado and North Carolina contain comparable regional clusters of companies in 
the life science industry.  A sectoral complementarity exists between Boulder and Denver, 
Colorado, and the Triad and Triangle, North Carolina where the proximate places benefit 
economically from the development of industry clusters.  Employment clusters were found here 
by collecting data from the BLS and ReferenceUSA company database for nine specified sectors 
covering R&D and various manufacturing activities.  These data, including latitude and longitude 
information for individual companies, helps visualize where firms of specified life science sectors 
are located.  The company location maps conclude that larger companies within Surgical and 
Medical Instrument Manufacturing are located in all three study MSAs in Colorado with more 
located in Denver-Aurora.  A dense concentration of R&D companies is found in the Boulder 
MSA and many in this sector are scattered throughout Denver-Aurora.  The pattern is similar for 
North Carolina where Surgical and Medical Instrument Manufacturing firms are found in both 
CSAs while R&D is concentrated more in the Triangle.  The Triangle is also home to several 
Pharmaceutical Preparation Manufacturing firms. 
   Each MSA‟s specialization in life sciences is more apparent when looking at calculated 
LQ‟s by NAICS code for each MSA.  Surgical and medical instrument manufacturing is the most 
dominant industry for both Boulder and Denver-Aurora, but the LQ is far higher in Boulder.  This 
sector is considered the specialization for both of these MSAs.  The LQ calculations also 
conclude that the Boulder MSA is the hub of life science and manufacturing activities in 
Colorado.  The Greeley MSA does not have a significant life science industry base.  The 
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hypothesis that each MSA develops its own specialization is more applicable to the North 
Carolina study area.  The LQs conclude that biological product manufacturing is the 
specialization in the Triad while it is surgical and medical instrument manufacturing in the 
Triangle (LQ of 12.18).  The Triangle specializes more in R&D than the Triad.  The Triad has a 
higher LQ for all the other manufacturing activities than the Triangle, except for pharmaceutical 
preparation manufacturing and laboratory apparatus and furniture manufacturing. 
 Commuting pattern statistics were compiled from the U.S. Census Bureau Transportation 
Planning Package to show a connection between the proximate regions of each study area and to 
demonstrate the general traits of a regional economic growth engine.  Small portions of all 
commuters were found to be traveling daily to work in the other proximate MSA or CSA in their 
region.  The strength of the research base of both study areas is demonstrated through the use of 
data from the NIH, including the highest-ranked institutions in terms of research grant funding.  
These research institutions provide highly trained and skilled scientists.  Nine universities from 
these regions are ranked in the top 500.  This is an indicator of the high quality of medical 
research and well educated labor force. Four universities receiving a total of $280,701,234 in 
grants are located in the Colorado study area.  Five receiving a total of $834,770,648 are in North 
Carolina.  Several schools in both study areas provide advanced degrees in life science fields.   
Data were collected from surveys conducted for North Carolina companies.  Several 
survey respondents noted proximity to local universities as the reason for their location decision.  
A majority of them also indicated an increase in R&D collaboration with universities.  Findings 
conclude that many companies are likely to seek resources from within their local region and 
contribute to the hypothesis that life science firms establish their locations in regional clusters and 
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develop strategies for innovation and collaboration to benefit from synergies and regional growth.  
Findings from these data sources indicate that characteristics of both states allow them to house 
proximate, complimentary regions where life science firms can become successful.  Synergies in 
both states exist between the proximate places to build regional economic growth engines. 
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APPENDIX A:  SURVEY: INNOVATION AND COLLABORATION IN LIFE SCIENCE 
FIRMS 
Background: 
1. Main area of business (check all that apply):  
 Diagnostic Therapeutic  Agri-Bio Environment  Other ___________ 
   
2. Is the company:  
 a subsidiary of a large firm    a spin off from a university Other_____________________ 
 
3. Is the company:  public    private  
 
4. When was the company established?  _______ 
 
5.   The total number of employees is (please estimate): __________ 
 
6. The total revenue for the most recent fiscal year is (check only one box.): 
  < $1 million     $1-10 million     $10.1-25 million       $25.1-50 million       > $50 million   
 
7.   What % of your company‟s total revenue is assigned to research and development (R&D) activity?         _%  
   
  If possible, please estimate the total dollars spent per year on R&D over the past 5 years: $_______________ 
     
8.   Do you export?  No    Yes, regularly  Yes, periodically   Plan to export in the future 
  
 If yes, what percentage of revenue comes from exports? __% 
 
Location:  
9.   Please list the top two reasons for locating your establishment where you are: 
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 Reason #1: _____________________________________________________________________         
 
 Reason #2: _____________________________________________________________________ 
 
10. Please list the most important form of local/state government assistance that benefits your operations: 
 
Local: _________________________________________________________________________  
 
State:  _________________________________________________________________________ 
 
11. What is the most essential type of government assistance that is missing and would be beneficial to 
your operations? 
 
Local: _________________________________________________________________________ 
 
State: _________________________________________________________________________ 
    
12. Is there a shortage of labor supply in the area?  No Yes 
If yes, in which occupational groups (please describe): 
 
Group 1: _____________________________________________________________ 
 
Group 2: _____________________________________________________________ 
 
Others:   _____________________________________________________________ 
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Collaborative Efforts: 
 
Collaboration is defined as formal partnerships in R&D, which include substantial contributions of time, capital, 
technology, or other assets.  Please answer the following questions as they relate to your company’s experience 
with collaboration: 
 
13. Is all R&D performed in-house?  No    Yes If no, please answer the following: 
      In the past 5 years, university R&D collaboration has  increased decreased remained the same 
      In the past 5 years, industry R&D collaboration has    increased decreased remained the same 
 
 14. Roughly what percentage of your R&D collaborators comes from the following geographic areas?  
  (Here, we are trying to assess the importance of local versus non-local R&D connections) 
     
Location of R&D  
collaborators 
University (percentage share of  
collaborators) 
Industry (percentage share of 
collaborators) 
Local % % 
State % % 
Elsewhere in the US % % 
International % % 
Total 100% 100% 
    
15. What is the main foreign country from where you have University collaborators? _____________________ 
 
16. What is the main foreign country from where you have Industry collaborators?   _____________________ 
 
Manufacturing and Sales: 
17. Does this firm operate with strategic alliances for manufacturing?  Yes  No   If yes, how many? ___ 
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Please indicate the location of manufacturing facilities:  
Location of manufacturing facility % of manufacturing 
Local city region            %  
Same state             % 
Elsewhere in the US            %  
International             % 
Total       100% 
 
18. If you have operations outside of the same city or region, please provide the main reasons:  
 
#1: _____________________________________________ 
 
#2: _____________________________________________ 
 
19. What are the difficulties in having a manufacturing operation or a partner in the same city or region?     
 
In-house difficulty: ____________________________________________________________________ 
 
Same city or region difficulty: _____________________________________________________________ 
 
 
 
 
 
Innovation: 
20.  Please indicate the approximate total number of innovations your company has achieved over the past 10 
years (or the period from company inception to present, if less than 10 years). 
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New products _______  New processes _______  Domestic patent approvals _______    
 
21. Please indicate the % of products in 3
rd
 stage clinical trial:  ____%  
 
22. Indicate the importance of the following strategies to your company (check one box per strategy from scale) 
 1=not important  2=minor importance  3=moderate importance  4=very important   5=critically important 
 
                            1      2       3      4      5         
a. Expand our research and development (R&D) effort   ........                        
b. Develop new products on a continual basis  ........................                        
c. Develop new processes on a continual basis .......................                        
d. Constantly improve our existing products ...........................                        
e. Obtain “early” technology from university researchers .......                                 
f. Develop R&D alliances with:  U.S. based universities ........                        
i. Foreign firms/universities                                                                  
Pharmaceutical companies                       
ii. Other biotech companies .                        
iii. Other companies (eg, chemical)                       
g. Collaborate with established pharma or chemical companies to: 
i. enhance credibility/reputation  ................................                        
ii. attract investors   .....................................................                                      
iii. access research/market information ........................                        
iv. develop products and manufacture .........................                        
v. access marketing/distribution channels  ..................                                 
h. License out technology ........................................................                          
i. License in technology ..........................................................                        
j. Aggressively seek American investors ................................                        
k. Aggressively seek foreign investment for US facilities .......                        
l. Manufacture our own products ............................................                        
m. Incorporate user feedback in the innovation process ...........                                 
n. Find new domestic clients  ...................................................                       
o. Develop strategic alliances with foreign firms for  
              distribution in foreign markets ...........................................                          
p. Establish manufacturing facilities in foreign countries ........                        
q. Enter foreign markets before competitors move in ..............                        
 
THANK YOU FOR TAKING THE TIME TO COMPLETE THIS SURVEY 
YOUR ASSISTANCE IS GREATLY APPRECIATED 
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A summary of this survey will be available in February 2008. The results will show overall trends only (no individuals or 
firms will be identified).  If you wish to receive a copy of the summary report, please attach your business card to this form or 
complete the mailing address section below.   
Can we call or e-mail you for clarification of a specific answer? 
   yes, call or e-mail  yes, I would like a copy of the completed report 
 
 
